In the field of rare diseases, discoveries exist. Expertise is available. Commitment is present. Yet innovation still struggles to spread. Stakeholders across the continuum (researchers, clinicians, expert patients, patient associations, foundations, industry players, start-ups and funding organisations) too often continue to operate in silos, extending already critical timelines.
It is estimated that, on average, fourteen years are required for an innovation emerging from research to reach patients. In the rare disease sector, where diagnosis takes an average of three years and 95% of conditions still have no treatment, the innovation challenge is even greater.
It is in this context that Symbiose Innovation was created, with the ambition of transforming current fragmentation into collective momentum.
A platform structured through Business Design
The platform and its associated services were developed following a rigorous analysis of the market, stakeholder needs and existing international initiatives. This structuring was carried out using the Business Design method, via the Vianeo platform and with the support of a consultant.
This approach made it possible to clarify the value proposition, model stakeholder segments, identify value creation levers and secure the project’s economic and strategic coherence. In other words: moving from an intention of impact to a structured and operational innovation model.
The difficulty was not believing in our project, but knowing where to begin.
“The Vianeo method enabled us to clarify our priorities and transform our vision into a clear, prioritised and economically coherent innovation model,” says Sandra Schnock, co-founder of Symbiose Innovation. The support was provided by Alexandre Menicacci, CEO of Ginseng and a certified practitioner of the method.
Bottlenecks clarified through Vianeo’s methodological support
Developing a collaborative platform project in the healthcare sector, bringing together a wide range of stakeholders, generated several bottlenecks that were clarified through methodological support.
Firstly, identifying priority personas proved more complex than expected. The support enabled these segments to be ranked and efforts to be focused on the most strategic targets.
Secondly, when conducting interviews with representatives of each persona, time with each stakeholder was limited, making it challenging to gain a detailed understanding of their needs, pain points and operational constraints. The Vianeo consultant helped structure these discussions, formulate the right hypotheses and distinguish weak signals from truly priority needs.
Finally, translating the value proposition into concrete platform functionalities, a coherent service offering and economic model hypotheses represented a critical stage. Work on feasibility, revenue scenarios and overall model coherence made it possible to move from an intuition of impact to a structured, testable and sustainable project architecture.
A digital hub to structure the ecosystem
Symbiose Innovation has just announced the official launch of its collaborative platform dedicated to rare diseases. Designed as an intelligent digital hub, it aims to catalogue and connect all stakeholders in innovation: scientific experts, clinicians, patient associations, industry players, solution providers and funders.
The platform offers:
- A structured directory of expertise, organisations, solutions and collaboration opportunities,
- An AI-enabled search engine facilitating targeted searches,
- A personalised matchmaking system,
- A space fostering the emergence of collaborative projects.
A dual approach: a platform and services
Beyond the digital platform, Symbiose Innovation is deploying a service offering structured around four pillars: Explore, Lead, Communicate, Finance.
Explore to map ecosystems and identify strategic partners.
Lead to structure, govern and secure collaborative projects.
Communicate to strengthen the visibility and attractiveness of initiatives.
Finance to identify and secure the financial resources required to deliver projects.
This integrated approach supports innovation stakeholders from analysing their environment through to the operational implementation of high-impact collaborations.
Professionalising collaboration in rare diseases
By structuring interactions and streamlining connections, Symbiose Innovation is part of a broader effort to professionalise healthcare innovation. The platform becomes a lever for translational research, project acceleration and the enhancement of expertise.
In a sector where scientific complexity is combined with social urgency, the ability to connect the right expertise at the right time becomes strategic.
With the launch of its platform, Symbiose Innovation is laying the foundations for a more connected, more transparent and more operational ecosystem, for the benefit of patients living with rare diseases and their families.
Find Symbiose at: www.symbioseinnovation.ca
